MX2016006053A - Compuestos selectivos de peptido yy (pyy) y usos de los mismos. - Google Patents
Compuestos selectivos de peptido yy (pyy) y usos de los mismos.Info
- Publication number
- MX2016006053A MX2016006053A MX2016006053A MX2016006053A MX2016006053A MX 2016006053 A MX2016006053 A MX 2016006053A MX 2016006053 A MX2016006053 A MX 2016006053A MX 2016006053 A MX2016006053 A MX 2016006053A MX 2016006053 A MX2016006053 A MX 2016006053A
- Authority
- MX
- Mexico
- Prior art keywords
- pyy compounds
- compounds
- selective
- hpyy
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
Abstract
La invención se refiere a compuestos de PYY que tienen el aminoácido en la posición que corresponde a la posición 30 del hPYY(1-36) sustituido por triptófano y derivados de los mismos con un grupo modificador unido a la posición que corresponde a la posición 7 del hPYY(1-36). Los compuestos de la invención son agonistas selectivos del receptor Y2. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos de PYY y excipientes farmacéuticamente aceptables, así como también el uso médico de los compuestos de PYY.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13193082 | 2013-11-15 | ||
US201361906020P | 2013-11-19 | 2013-11-19 | |
EP14176725 | 2014-07-11 | ||
PCT/EP2014/074476 WO2015071355A1 (en) | 2013-11-15 | 2014-11-13 | Selective pyy compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016006053A true MX2016006053A (es) | 2016-08-17 |
MX369818B MX369818B (es) | 2019-11-22 |
Family
ID=53056816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006053A MX369818B (es) | 2013-11-15 | 2014-11-13 | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9085637B2 (es) |
EP (1) | EP3068421B1 (es) |
JP (1) | JP6602760B2 (es) |
KR (1) | KR20160075819A (es) |
CN (1) | CN105722526B (es) |
AU (1) | AU2014350197B2 (es) |
BR (1) | BR112016010383A2 (es) |
CA (1) | CA2929672A1 (es) |
IL (1) | IL245045B (es) |
MX (1) | MX369818B (es) |
PL (1) | PL3068421T3 (es) |
RS (1) | RS59026B1 (es) |
SI (1) | SI3068421T1 (es) |
TW (1) | TWI661835B (es) |
WO (1) | WO2015071355A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3326620B1 (en) | 2010-12-16 | 2020-03-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid |
EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
US20160108098A1 (en) * | 2013-05-02 | 2016-04-21 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
EP3068795B1 (en) | 2013-11-15 | 2019-03-06 | Novo Nordisk A/S | Hpyy(1-36) having a beta-homoarginine substitution at position 35 |
US9085637B2 (en) * | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
TWI694082B (zh) * | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
HRP20221150T1 (hr) | 2016-04-28 | 2022-11-25 | Novo Nordisk A/S | Semaglutid u kardiovaskularnim stanjima |
EP3534962B1 (en) | 2016-11-07 | 2020-08-19 | Novo Nordisk A/S | Dchbs-active esters of peg compounds and their use |
CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
US20200165313A1 (en) | 2017-07-19 | 2020-05-28 | Novo Nordisk A/S | Egf(a) analogues, preparation, formulations and uses thereof |
WO2019106193A1 (en) | 2017-12-01 | 2019-06-06 | University Of Copenhagen | Peptide hormone with one or more o-glycans |
BR112020013733A2 (pt) * | 2018-01-09 | 2020-12-01 | Gila Therapeutics, Inc. | composições e métodos para tratar doenças metabólicas |
PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
EP4009957B1 (en) * | 2019-08-07 | 2023-10-11 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | NPY2 RECEPTOR AGONISTS |
KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2157766A1 (en) | 1993-03-29 | 1994-10-13 | Ambikaipakan Balasubramaniam | Analogs of peptide yy and uses thereof |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
AU1159897A (en) | 1996-11-13 | 1998-06-03 | University Of Cincinnati, The | Analogs of peptide yy and uses thereof |
EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
CA2334298C (en) | 1998-06-08 | 2008-01-08 | Schering Corporation | Neuropeptide y5 receptor antagonists |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
BR0116206A (pt) | 2000-12-14 | 2003-12-23 | Amylin Pharmaceuticals Inc | Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos |
US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
DE60230818D1 (de) | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
WO2004066966A2 (en) | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
CN101380476A (zh) | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
CA2550050A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
EP2335716A3 (en) | 2004-02-11 | 2011-10-19 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
EP2417980A1 (en) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP1729792B1 (en) | 2004-03-17 | 2010-12-08 | 7TM Pharma A/S | Y4 selective receptor agonist for therapeutic interventions |
WO2005089789A2 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
CN101361967A (zh) | 2004-03-17 | 2009-02-11 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2/y4选择性受体激动剂 |
US20080261871A1 (en) | 2004-03-17 | 2008-10-23 | 7Tm Pharma A/S | Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
RU2006144821A (ru) | 2004-07-08 | 2008-08-20 | Ново Нордиск А/С (DK) | Пролонгирующие метки полипептидов, содержащие тетразольную группировку |
WO2006020207A2 (en) | 2004-07-19 | 2006-02-23 | University Of Cincinnati | Compounds for control of appetite |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JP2009500453A (ja) | 2005-07-11 | 2009-01-08 | ナステック ファーマスーティカル カンパニー インク. | 向上されたpyyの粘膜送達用製剤 |
EP1907010A2 (en) | 2005-07-18 | 2008-04-09 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
WO2007038943A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
US8022035B2 (en) | 2005-09-21 | 2011-09-20 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
EP1962959B1 (en) | 2005-12-07 | 2012-03-14 | F. Hoffmann-La Roche AG | Neuropeptide-2 receptor-agonists |
EP1963343A1 (en) | 2005-12-14 | 2008-09-03 | Novo Nordisk A/S | Polypeptide protracting tags |
US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
EP2322620A3 (en) | 2007-07-09 | 2011-08-31 | Imperial Innovations Ltd. | Analogs of human pancreatic polypeptide and their effects on feeding behaviour |
US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
US20100204113A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of stresscopin-related peptide as a therapeutic agent |
US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
CA2723855A1 (en) | 2008-05-16 | 2009-11-19 | Novo Nordisk A/S | Long-acting y2 and/or y4 receptor agonists |
US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
MX2011004427A (es) * | 2008-11-05 | 2011-05-31 | Hoffmann La Roche | Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos. |
CN102325545A (zh) | 2009-02-20 | 2012-01-18 | 益普生制药股份有限公司 | 具有神经肽y受体结合化合物的细胞毒性缀合物 |
EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
CN102596228A (zh) | 2009-10-13 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 神经肽-2受体(y-2r)激动剂 |
US20130096055A1 (en) * | 2009-11-13 | 2013-04-18 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
WO2011131646A1 (en) | 2010-04-20 | 2011-10-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
ES2935300T3 (es) * | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
WO2013178490A1 (en) | 2012-05-29 | 2013-12-05 | Novo Nordisk A/S | Pancreatic polypeptide compounds and use |
US20160108098A1 (en) * | 2013-05-02 | 2016-04-21 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
EP3068795B1 (en) | 2013-11-15 | 2019-03-06 | Novo Nordisk A/S | Hpyy(1-36) having a beta-homoarginine substitution at position 35 |
TWI694082B (zh) * | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
-
2014
- 2014-11-13 US US14/540,474 patent/US9085637B2/en active Active
- 2014-11-13 CA CA2929672A patent/CA2929672A1/en not_active Withdrawn
- 2014-11-13 TW TW103139321A patent/TWI661835B/zh not_active IP Right Cessation
- 2014-11-13 RS RS20190792A patent/RS59026B1/sr unknown
- 2014-11-13 US US15/036,201 patent/US10246497B2/en active Active
- 2014-11-13 PL PL14798834T patent/PL3068421T3/pl unknown
- 2014-11-13 CN CN201480062213.5A patent/CN105722526B/zh active Active
- 2014-11-13 WO PCT/EP2014/074476 patent/WO2015071355A1/en active Application Filing
- 2014-11-13 KR KR1020167015805A patent/KR20160075819A/ko not_active Application Discontinuation
- 2014-11-13 AU AU2014350197A patent/AU2014350197B2/en not_active Ceased
- 2014-11-13 BR BR112016010383A patent/BR112016010383A2/pt not_active Application Discontinuation
- 2014-11-13 EP EP14798834.9A patent/EP3068421B1/en active Active
- 2014-11-13 JP JP2016531028A patent/JP6602760B2/ja active Active
- 2014-11-13 MX MX2016006053A patent/MX369818B/es active IP Right Grant
- 2014-11-13 SI SI201431251T patent/SI3068421T1/sl unknown
-
2016
- 2016-04-11 IL IL245045A patent/IL245045B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP3068421B1 (en) | 2019-04-17 |
TWI661835B (zh) | 2019-06-11 |
WO2015071355A1 (en) | 2015-05-21 |
MX369818B (es) | 2019-11-22 |
KR20160075819A (ko) | 2016-06-29 |
JP2017505284A (ja) | 2017-02-16 |
IL245045B (en) | 2019-09-26 |
US10246497B2 (en) | 2019-04-02 |
US20150152150A1 (en) | 2015-06-04 |
AU2014350197A1 (en) | 2016-05-05 |
US20160289283A1 (en) | 2016-10-06 |
JP6602760B2 (ja) | 2019-11-06 |
CN105722526B (zh) | 2020-12-08 |
BR112016010383A2 (pt) | 2017-12-05 |
PL3068421T3 (pl) | 2019-11-29 |
TW201605467A (zh) | 2016-02-16 |
US9085637B2 (en) | 2015-07-21 |
AU2014350197B2 (en) | 2018-10-04 |
CA2929672A1 (en) | 2015-05-21 |
SI3068421T1 (sl) | 2019-08-30 |
EP3068421A1 (en) | 2016-09-21 |
RS59026B1 (sr) | 2019-08-30 |
IL245045A0 (en) | 2016-05-31 |
CN105722526A (zh) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
MY181181A (en) | Fgf21 derivatives and uses thereof | |
CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
PH12015500823A1 (en) | Modified release formulations for oprozomib | |
UA117154C2 (uk) | Антагоністи s1p3 | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
PH12017501736A1 (en) | Indole derivatives | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
MX2015006997A (es) | Composicion farmaceutica. | |
PH12016502527A1 (en) | Stabilized desmopressin | |
TR201721065A2 (tr) | Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar | |
GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα | |
IN2013MU03656A (es) | ||
UA114792C2 (uk) | Коагоніст глюкагонового рецептора/glp-1-рецептора |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |